Noveome Biotherapeutics, Inc. — SEC Form D Filing

Noveome Biotherapeutics, Inc. filed an SEC Form D on August 27, 2026, reporting $6.75M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
August 27, 2026
Amount reported
$6.75M
Round stage
Series B+
Industry
Biotechnology
Website
https://noveome.com/

What the company does

Securities: Debt, Convertible promissory notes. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Premature infants can suffer from Necrotizing Enterocolitis (NEC), a serious condition.

Solution

Noveome Biotherapeutics is developing ST266, a multi-targeted biologic secretome designed to promote neuroprotection, modulate inflammation, and support cell recovery and healing.

Verdict

Investors backed a multi-targeted biologic approach for a severe, unmet medical need in a vulnerable population. This cleared because the narrative promised broad therapeutic impact from a single agent, not because it presented a novel delivery mechanism or a rapidly scalable platform. Investors were implicitly betting on the biological efficacy of ST266 across multiple pathways and the team's ability to navigate complex clinical development for a highly specific pediatric indication. The upside was inherently limited by the niche patient population for Necrotizing Enterocolitis (NEC) and the long, capital-intensive development timelines typical of biologics.

Source: SEC EDGAR Form D filing